Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NeuroMetrix Inc NURO

Healthcare Medical Devices
NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two... see more

Recent & Breaking News (NDAQ:NURO)

NeuroMetrix, Inc. Announces Date for First Quarter 2021 Financial Results Conference Call

GlobeNewswire April 15, 2021

NeuroMetrix Reports Q4 and Full Year 2020 Financial Results

GlobeNewswire January 28, 2021

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2020 Financial Results Conference Call

GlobeNewswire January 22, 2021

NeuroMetrix Reports Q3 2020 Financial Results

GlobeNewswire October 22, 2020

NeuroMetrix, Inc. Announces Date for Third Quarter 2020 Financial Results Conference Call

GlobeNewswire October 15, 2020

NeuroMetrix Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-the-Counter Pain Relief Device

GlobeNewswire September 22, 2020

NeuroMetrix Announces Issuance of New U.S. Patent for Quell® Wearable Technology

GlobeNewswire September 21, 2020

NeuroMetrix Reports Scientific Presentation at the PAINWeek 2020 Live Virtual Conference

GlobeNewswire September 4, 2020

NeuroMetrix Reports Publication of Study Validating DPNCheck® Staging of Diabetic Peripheral Neuropathy Severity

GlobeNewswire September 1, 2020

NeuroMetrix Reports that Quell® is to be Evaluated for Chemotherapy-Induced Peripheral Neuropathy in NIH-Funded Clinical Trial

GlobeNewswire August 20, 2020

Quell® Fills Unmet Need for Chronic Knee Pain Relief that is Drug-Free

GlobeNewswire August 10, 2020

NeuroMetrix Reports Q2 2020 Financial Results

GlobeNewswire July 23, 2020

NeuroMetrix, Inc. Announces Date for Second Quarter 2020 Financial Results Conference Call

GlobeNewswire July 16, 2020

NeuroMetrix Reports DPNCheck® Expansion in China

GlobeNewswire July 9, 2020

NeuroMetrix Signs DPNCheck® Collaboration Agreement with Biomedix

GlobeNewswire June 25, 2020

NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief Device

GlobeNewswire June 10, 2020

NeuroMetrix Reports Q1 2020 Financial Results

GlobeNewswire April 23, 2020

NeuroMetrix Reports Quell® Technology to be Used in NIH-Funded Trial Evaluating Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) for Fibromyalgia

GlobeNewswire April 16, 2020

NeuroMetrix, Inc. Announces Date for First Quarter 2020 Financial Results Conference Call

GlobeNewswire April 16, 2020

NeuroMetrix Announces 2020 Annual Meeting of Shareholders Will Be Held in Virtual Meeting Format Only

GlobeNewswire April 10, 2020